News

New research examining the prevalence of chronic traumatic encephalopathy among former NFL players provides additional insight into CTE pathology, while highlighting the challenges of interpreting findings from postmortem brain-donation studies.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Findings showed that remibrutinib outperformed teriflunomide in the REMODEL-1 and REMODEL-2 phase 3 trials among adults with relapsing MS, lowering relapse rates and MRI lesions with a favorable safety profile.

Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.

A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy from 2026, 5 headlines compiled in one place by the NeurologyLive® team.

Neurology News Network for the week ending August 29th, 2026. [WATCH TIME: 5 minutes]

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 28, 2026.

The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval and how restoring orexin signaling may reshape treatment expectations in narcolepsy type 1.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® reviews the investigational agents currently moving through clinical development for spinal muscular atrophy.

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Jacqueline Rosenthal, MD, to discuss the medical uses of botulinum toxin across neurologic conditions, including chronic migraine and spasticity, as well as treatment expectations, shared decision-making, and common misconceptions surrounding Botox.

The phase 3 clinical program for salanersen, an investigational intrathecally administered antisense oligonucleotide, will test the efficacy of the agent across infants, adolescents and adults living with SMA.

Cellenkos’ investigational allogeneic, cord blood-derived T-regulatory cell therapy is being evaluated in a phase 1/1b study in ALS, with early findings showing reductions in plasma neurofilament light chain and increases in IL-10.

The American Heart Association and American Stroke Association have published an updated, comprehensive guideline for adult stroke rehabilitation, replacing the 2016 version with new and revised recommendations spanning the full recovery continuum.

Brian Lin, PhD, Research Director at the Muscular Dystrophy Association, commented on the first-ever clinical trial framework for Charcot-Marie-Tooth disease, what it means for drug developers, and where the field's biomarker and endpoint evidence still needs to grow.

The FDA has granted De Novo Authorization to Avulux's optical-filter lenses to reduce light sensitivity in patients aged 12 years or older with episodic migraine.

Nestor Galvez-Jimenez, MD, a neurologist at Baptist Health Miami Neuroscience Institute, discussed how advancements have changed the landscape of care for patients living with spinal muscular atrophy.

Erika Trovato, DO, MS, program director of the Brain Injury Medicine Fellowship at Burke Rehabilitation Hospital, provided clinical advice for trainees and early-career physicians looking to establish themselves in the field.

Regenxbio recently announced that the FDA placed RGX-121 on hold after spinal MRI abnormalities emerged in 5 participants with MPS II and does not expect a near-term BLA filing.

The designation for the investigational brain-penetrant IDH1 inhibitor comes as the pivotal phase 3 SIGMA study evaluates its use in patients with high-risk IDH1-mutant astrocytoma.